MoonLake Non Operating Income Net Other from 2010 to 2026
| MLTX Stock | USD 15.77 0.16 1.02% |
Non Operating Income Net Other | First Reported 2010-12-31 | Previous Quarter 680.5 K | Current Value 340.7 K | Quarterly Volatility 257.8 K |
Check MoonLake Immunotherapeuti financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MoonLake Immunotherapeuti's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Other Operating Expenses of 172.8 M or Total Operating Expenses of 172.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.2. MoonLake financial statements analysis is a perfect complement when working with MoonLake Immunotherapeuti Valuation or Volatility modules.
MoonLake | Non Operating Income Net Other | Build AI portfolio with MoonLake Stock |
The evolution of Non Operating Income Net Other for MoonLake Immunotherapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how MoonLake Immunotherapeuti compares to historical norms and industry peers.
Latest MoonLake Immunotherapeuti's Non Operating Income Net Other Growth Pattern
Below is the plot of the Non Operating Income Net Other of MoonLake Immunotherapeutics over the last few years. It is MoonLake Immunotherapeuti's Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MoonLake Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
| Non Operating Income Net Other | 10 Years Trend |
|
Non Operating Income Net Other |
| Timeline |
MoonLake Non Operating Income Net Other Regression Statistics
| Arithmetic Mean | 184,039 | |
| Geometric Mean | 66,515 | |
| Coefficient Of Variation | 140.05 | |
| Mean Deviation | 220,727 | |
| Median | 27,691 | |
| Standard Deviation | 257,752 | |
| Sample Variance | 66.4B | |
| Range | 652.8K | |
| R-Value | 0.75 | |
| Mean Square Error | 31.4B | |
| R-Squared | 0.56 | |
| Significance | 0.0006 | |
| Slope | 38,074 | |
| Total Sum of Squares | 1.1T |
MoonLake Non Operating Income Net Other History
About MoonLake Immunotherapeuti Financial Statements
MoonLake Immunotherapeuti investors use historical fundamental indicators, such as MoonLake Immunotherapeuti's Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MoonLake Immunotherapeuti. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Operating Income Net Other | 680.5 K | 340.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.